Galapagos Nv (GLPG)

$31.07

+0.31

(+1.01%)▲

Live

Performance

  • $30.49
    $31.07
    $31.07
    downward going graph

    1.87%

    Downside

    Day's Volatility :1.87%

    Upside

    0.0%

    downward going graph
  • $24.16
    $42.46
    $31.07
    downward going graph

    22.24%

    Downside

    52 Weeks Volatility :43.09%

    Upside

    26.82%

    downward going graph

Returns

PeriodGalapagos NvSector (Health Care)Index (Russel 2000)
3 Months
12.96%
3.6%
0.0%
6 Months
5.81%
10.2%
0.0%
1 Year
-10.19%
19.6%
0.0%
3 Years
-40.78%
16.8%
-23.0%

Highlights

Market Capitalization
2.0B
Book Value
$44.16
Earnings Per Share (EPS)
0.52
PE Ratio
58.15
PEG Ratio
0.0
Wall Street Target Price
30.75
Profit Margin
108.11%
Operating Margin TTM
-49.03%
Return On Assets TTM
-1.76%
Return On Equity TTM
1.15%
Revenue TTM
261.4M
Revenue Per Share TTM
0.2
Quarterly Revenue Growth YOY
29.7%
Gross Profit TTM
4.8M
EBITDA
-101.3M
Diluted Eps TTM
0.52
Quarterly Earnings Growth YOY
0.75
EPS Estimate Current Year
0.23
EPS Estimate Next Year
-0.6
EPS Estimate Current Quarter
-0.04
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Hold
    38%Buy
    61%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Galapagos Nv(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
11
11
10
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 1.03%

Current $31.07
Target $30.75

Company Financials

FY18Y/Y Change
Revenue
328.6M
↑ 127.27%
Net Income
-33.3M
↓ 74.71%
Net Profit Margin
-10.13%
↑ 80.91%
FY19Y/Y Change
Revenue
939.0M
↑ 192.55%
Net Income
166.5M
↓ 612.13%
Net Profit Margin
17.73%
↑ 27.86%
FY20Y/Y Change
Revenue
581.5M
↓ 43.42%
Net Income
-378.3M
↓ 307.55%
Net Profit Margin
-65.06%
↓ 82.79%
FY21Y/Y Change
Revenue
548.1M
↑ 1.42%
Net Income
-141.8M
↓ 59.67%
Net Profit Margin
-25.87%
↑ 39.19%
FY22Y/Y Change
Revenue
534.7M
↑ 4.21%
Net Income
-230.7M
↑ 73.81%
Net Profit Margin
-43.14%
↓ 17.27%
FY23Y/Y Change
Revenue
261.5M
↓ 52.56%
Net Income
230.9M
↓ 197.11%
Net Profit Margin
88.31%
↑ 131.45%
Q1 FY23Q/Q Change
Revenue
191.4M
↑ 88.04%
Net Income
24.8M
↓ 111.2%
Net Profit Margin
12.97%
↑ 230.81%
Q2 FY23Q/Q Change
Revenue
162.7M
↓ 16.17%
Net Income
5.5M
↓ 78.02%
Net Profit Margin
3.4%
↓ 9.57%
Q3 FY23Q/Q Change
Revenue
128.1M
↓ 19.96%
Net Income
27.6M
↑ 406.37%
Net Profit Margin
21.52%
↑ 18.12%
Q4 FY23Q/Q Change
Revenue
-228.1M
↓ 274.23%
Net Income
171.9M
↑ 509.98%
Net Profit Margin
-75.34%
↓ 96.86%
Q1 FY24Q/Q Change
Revenue
84.6M
↓ 137.24%
Net Income
9.8M
↓ 94.3%
Net Profit Margin
11.54%
↑ 86.88%
Q2 FY24Q/Q Change
Revenue
83.8M
↑ 0.0%
Net Income
9.7M
↑ 0.0%
Net Profit Margin
11.54%
↑ 0.0%
FY18Y/Y Change
Total Assets
1.6B
↑ 11.91%
Total Liabilities
256.2M
↓ 17.88%
FY19Y/Y Change
Total Assets
6.7B
↑ 321.58%
Total Liabilities
3.5B
↑ 1317.53%
FY20Y/Y Change
Total Assets
7.0B
↓ 5.78%
Total Liabilities
3.7B
↓ 4.56%
FY21Y/Y Change
Total Assets
5.9B
↓ 9.17%
Total Liabilities
2.9B
↓ 16.33%
FY22Y/Y Change
Total Assets
5.0B
↓ 8.83%
Total Liabilities
2.3B
↓ 13.39%
FY23Y/Y Change
Total Assets
4.8B
↓ 7.96%
Total Liabilities
1.7B
↓ 29.28%
Q1 FY23Q/Q Change
Total Assets
5.0B
↓ 2.16%
Total Liabilities
2.2B
↓ 6.37%
Q2 FY23Q/Q Change
Total Assets
4.9B
↓ 2.37%
Total Liabilities
2.1B
↓ 6.25%
Q3 FY23Q/Q Change
Total Assets
4.8B
↓ 1.57%
Total Liabilities
2.0B
↓ 5.6%
Q4 FY23Q/Q Change
Total Assets
4.8B
↓ 2.11%
Total Liabilities
1.7B
↓ 14.64%
Q1 FY24Q/Q Change
Total Assets
4.7B
↓ 1.54%
Total Liabilities
1.5B
↓ 11.64%
Q2 FY24Q/Q Change
Total Assets
4.6B
↑ 0.0%
Total Liabilities
1.5B
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-162.1M
↓ 3.1%
Investing Cash Flow
-18.1M
↑ 2798.72%
Financing Cash Flow
327.5M
↓ 18.53%
FY19Y/Y Change
Operating Cash Flow
3.6B
↓ 2352.2%
Investing Cash Flow
-4.2B
↑ 23556.28%
Financing Cash Flow
1.5B
↑ 364.0%
FY20Y/Y Change
Operating Cash Flow
-519.8M
↓ 113.32%
Investing Cash Flow
921.1M
↓ 120.12%
Financing Cash Flow
26.8M
↓ 98.35%
FY21Y/Y Change
Operating Cash Flow
-569.6M
↑ 17.9%
Investing Cash Flow
611.8M
↓ 28.53%
Financing Cash Flow
-4.4M
↓ 117.59%
FY22Y/Y Change
Operating Cash Flow
-529.7M
↓ 0.65%
Investing Cash Flow
-1.3B
↓ 330.12%
Financing Cash Flow
-1.6M
↓ 61.64%
Q1 FY23Q/Q Change
Operating Cash Flow
-101.5M
↓ 47.26%
Investing Cash Flow
195.4M
↑ 907.88%
Financing Cash Flow
-203.4K
↓ 90.1%
Q2 FY23Q/Q Change
Operating Cash Flow
-136.0M
↑ 32.2%
Investing Cash Flow
198.0M
↑ 0.0%
Financing Cash Flow
-1.7M
↑ 716.32%
Q3 FY23Q/Q Change
Operating Cash Flow
-126.8M
↓ 5.26%
Investing Cash Flow
194.9M
↑ 0.0%
Financing Cash Flow
-2.2M
↑ 33.4%

Technicals Summary

Sell

Neutral

Buy

Galapagos Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Galapagos Nv
Galapagos Nv
5.09%
5.81%
-10.19%
-40.78%
-80.47%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Galapagos Nv
Galapagos Nv
58.15
58.15
0.0
0.23
0.01
-0.02
NA
44.16
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Galapagos Nv
Galapagos Nv
Hold
$2.0B
-80.47%
58.15
108.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Galapagos Nv

  • Increasing Revenue

    Revenue is up for the last 3 quarters, -209.12M → 77.87M (in $), with an average increase of 184.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 157.55M → 8.98M (in $), with an average decrease of 47.2% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 95.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 85.6%

Institutional Holdings

  • EcoR1 Capital, LLC

    8.74%

  • FMR Inc

    4.38%

  • Bvf Inc

    2.38%

  • Deerfield Management Co

    2.14%

  • Prosight Management, LP

    2.05%

  • Segall Bryant & Hamill

    1.21%

Company Information

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Organization
Galapagos Nv
Employees
683
CEO
Dr. Paulus A. Stoffels M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs